About Avadel Pharmaceuticals
Avadel Pharmaceuticals is a company based in Dublin (Ireland) founded in 1990 was acquired by Alkermes in October 2025. The company has 188 employees as of December 31, 2024. Avadel Pharmaceuticals has completed 1 acquisition, including Eclat Pharmaceuticals. Avadel Pharmaceuticals operates in a competitive market with competitors including Sirnaomics, Apnimed, Ensysce, Oxular and Arecor, among others.
- Headquarter Dublin, Ireland
- Employees 188 as on 31 Dec, 2024
- Stage Public
-
Sectors
HealthcareTechnology
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Avadel Pharmaceuticals Plc
-
Annual Revenue
$169.12 M (USD)504.79as on Dec 31, 2024
-
Net Profit
-$48.83 M (USD)69.53as on Dec 31, 2024
-
EBITDA
-$39.72 M (USD)70.81as on Dec 31, 2024
-
Latest Funding Round
$117.4 M (USD), Post-IPO
Mar 09, 2022
-
Investors
Alkermes
& 5 more
-
Employee Count
188
as on Dec 31, 2024
- Investments & Acquisitions
-
Acquired by
Alkermes
(Oct 22, 2025)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of Avadel Pharmaceuticals
Avadel Pharmaceuticals is a publicly listed company on the NASDAQ with ticker symbol AVDL in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
People of Avadel Pharmaceuticals
Unlock access to complete
Unlock access to complete
Funding Insights of Avadel Pharmaceuticals
Investors in Avadel Pharmaceuticals
Avadel Pharmaceuticals has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Alkermes, RTW Investments and Vivo Capital.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital and private equity firm
|
Locked | Locked | Locked | |
|
Venture capital fund focused on biotechnology startups
|
Locked | Locked | Locked | |
|
Life Sciences focused VC firm investing in the US
|
Locked | Locked | Locked |
Investor details for Avadel Pharmaceuticals
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Avadel Pharmaceuticals
Avadel Pharmaceuticals has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Eclat Pharmaceuticals.
Investment portfolio details for Avadel Pharmaceuticals
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Gasket sheets and sealing solutions are manufactured for industrial applications.
|
Locked | Locked | 2010 | Locked |
Complete acquisition details for Avadel Pharmaceuticals
Transaction dates, acquired stakes, disclosed values, domains, and locations require an active premium plan.
- Transaction dates
- Acquired stakes
- Disclosed values
- Domains and locations
Verified entity values are shown only after access is granted.
Financial Statements - Avadel Pharmaceuticals
Detailed financials for Avadel Pharmaceuticals
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Avadel Pharmaceuticals Comparisons
Peer comparison for Avadel Pharmaceuticals
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Avadel Pharmaceuticals
Avadel Pharmaceuticals operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Sirnaomics, Apnimed, Ensysce, Oxular and Arecor, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
RNA-based therapeutics for cancer and fibrosis are developed.
|
|
| Locked | Locked | Locked |
Small molecule therapeutics for obstructive sleep apnea are developed.
|
|
| Locked | Locked | Locked |
Drug delivery solutions via single-walled carbon nanotubes are offered.
|
|
| Locked | Locked | Locked |
Drug delivery platforms and therapeutics for ophthalmology are developed.
|
|
| Locked | Locked | Locked |
Developer of proteins, vaccines based on proprietary stabilization technologies for drug delivery
|
|
| Locked | Locked | Locked |
RNAi technologies are developed for treating rare orphan diseases.
|
Detailed competitors of Avadel Pharmaceuticals
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Avadel Pharmaceuticals
Complete news archive for Avadel Pharmaceuticals
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Avadel Pharmaceuticals
Avadel Pharmaceuticals was founded in 1990 and raised its 1st funding round 28 years after it was founded.
Avadel Pharmaceuticals is headquartered in Dublin, Ireland.
Gregory J Divis is the current CEO of Avadel Pharmaceuticals.
As of Dec 31, 2024, the latest employee count at Avadel Pharmaceuticals is 188.
Annual revenue of Avadel Pharmaceuticals is $169.12M as on Dec 31, 2024.
Pharma company with proprietary drug delivery tools and drugs for narcolepsy. The company is involved in the development of its lead candidate FT218, which is a once nightly formulation of sodium oxybate designed to treat narcolepsy sleeping disorder. The company is also involved in commercialized some hospital (mainly injectables) and pediatric (oral formulations) care products. The company offers 4 main drug delivery technologies - micropump (precisely delayed drug release microcapsules), liquitime (oral liquid formulation with delayed-release formulation), triggerlock (a mechanism to prevent abuse in opiate analgesics), and medusa (hydrogel depot formulation for subcutaneous injections).
Avadel Pharmaceuticals's top competitors include Sirnaomics, Arcturus Therapeutics and Apnimed.
Yes, Avadel Pharmaceuticals is publicly traded on NASDAQ under the ticker symbol AVDL.
Avadel Pharmaceuticals has made 1 acquisition, including Eclat Pharmaceuticals.
Avadel Pharmaceuticals has 6 investors. Key investors include Alkermes, RTW Investments, Vivo Capital, Avoro Capital Advisors, and Acuta Capital Partners.
The ticker symbol of Avadel Pharmaceuticals is AVDL on NASDAQ.